Contact
searchSearch
HMP Global

Welcome to the Masterclasses in Dermatology Newsroom!

Discover the ultimate dermatology learning experience in beautiful Sarasota, FL! Designed by leading experts, this exclusive, interdisciplinary event offers four days of accredited CME tailored for those ready to deepen their knowledge and sharpen their skills. Elevate your expertise and set yourself apart—this is the dermatology event you don’t want to miss.

wells
Clinical Insights
Addressing Unmet Needs in Psoriatic Arthritis: Diagnosis, Pathogenesis, and Newer/Emerging Oral Therapies
03/02/2026
Hermon Feron, BA; Victoria Garfinkel, BSA
Dr Wells delivered a forward-thinking discussion on psoriatic arthritis, emphasizing that up to 30% of patients with psoriasis develop PsA and reinforcing that psoriasis is a systemic inflammatory disease rather than a condition limited to...
Dr Wells delivered a forward-thinking discussion on psoriatic arthritis, emphasizing that up to 30% of patients with psoriasis develop PsA and reinforcing that psoriasis is a systemic inflammatory disease rather than a condition limited to...
Dr Wells delivered a...
03/02/2026
The Dermatologist
Blauvelt
Clinical Insights
Transforming Psoriasis Care: Oral IL-23 Therapy and the Next Frontier in Patient-Centered Treatment
03/02/2026
Hermon Feron, BA; Victoria Garfinkel, BSA
Dr Blauvelt emphasized that psoriasis should be approached as a whole-person disease, one that affects mental health and is associated with systemic comorbidities, including metabolic syndrome, diabetes, cardiovascular disease, inflammatory...
Dr Blauvelt emphasized that psoriasis should be approached as a whole-person disease, one that affects mental health and is associated with systemic comorbidities, including metabolic syndrome, diabetes, cardiovascular disease, inflammatory...
Dr Blauvelt emphasized that...
03/02/2026
The Dermatologist
Werth
Clinical Insights
Advances in Dermatomyositis: The Evolving Landscape and Potential Role of Novel Therapies to Improve Disease Outcomes
03/02/2026
Hermon Feron, BA; Victoria Garfinkel, BSA
Dermatomyositis is a systemic autoimmune myopathy with prominent cutaneous features and significant heterogeneity across organ involvement, autoantibody profiles, and disease course.
Dermatomyositis is a systemic autoimmune myopathy with prominent cutaneous features and significant heterogeneity across organ involvement, autoantibody profiles, and disease course.
Dermatomyositis is a systemic...
03/02/2026
The Dermatologist
Gottlieb
Clinical Insights
Reimagining Hidradenitis Suppurativa Care: Early Recognition, Therapeutic Innovation, and Multidisciplinary Care Across the Patient Journey
03/02/2026
Hermon Feron, BA; Victoria Garfinkel, BSA
During an expert discussion, speakers emphasized that improving outcomes in HS requires earlier recognition, reduction of diagnostic delay, coordinated referral systems, and integration of medical and surgical management across the disease...
During an expert discussion, speakers emphasized that improving outcomes in HS requires earlier recognition, reduction of diagnostic delay, coordinated referral systems, and integration of medical and surgical management across the disease...
During an expert discussion,...
03/02/2026
The Dermatologist
Asempa
Clinical Insights
Advancing Inclusive Outcome Measures in Dermatology
03/02/2026
Hermon Feron, BA; Victoria Garfinkel, BSA
In a recent panel discussion, Dr Asempa and Dr Alexis emphasized that without inclusive trial design and culturally responsive terminology, we risk biased severity assessments and inequitable treatment decisions.
In a recent panel discussion, Dr Asempa and Dr Alexis emphasized that without inclusive trial design and culturally responsive terminology, we risk biased severity assessments and inequitable treatment decisions.
In a recent panel discussion, Dr...
03/02/2026
The Dermatologist
Krueger
Clinical Insights
Advancing Oral Therapies in Psoriasis: Targeted Innovation for Improved Disease Control and Patient Adherence
03/02/2026
Hermon Feron, BA; Victoria Garfinkel, BSA
At a recent session led by Dr Krueger and Dr Glick, evolving strategies for evaluating and treating moderate-to-severe psoriasis were highlighted, with particular attention to high-impact areas such as the scalp, face, nails, palms/soles, and...
At a recent session led by Dr Krueger and Dr Glick, evolving strategies for evaluating and treating moderate-to-severe psoriasis were highlighted, with particular attention to high-impact areas such as the scalp, face, nails, palms/soles, and...
At a recent session led by Dr...
03/02/2026
The Dermatologist
Yosipovitch
Clinical Insights
Rapid Neuromodulation and Mast Cell Targeting in Chronic Pruritus
03/02/2026
Hermon Feron, BA; Victoria Garfinkel, BSA
Dr Yosipovitch emphasized that effective itch management requires directly targeting neuronal signaling pathways and mast cell activation, particularly in itch-dominant diseases such as prurigo nodularis.
Dr Yosipovitch emphasized that effective itch management requires directly targeting neuronal signaling pathways and mast cell activation, particularly in itch-dominant diseases such as prurigo nodularis.
Dr Yosipovitch emphasized that...
03/02/2026
The Dermatologist
Yoo
Clinical Insights
Ultrasound as a Transformative Tool in Dermatology: From Cosmetic Imaging to Hidradenitis Suppurativa Assessment and Emerging Therapies
03/02/2026
Hermon Feron, BA; Victoria Garfinkel, BSA
Dr Yoo and Dr Gottlieb reviewed the principles and applications of handheld ultrasound devices, sonographic assessment of hidradenitis suppurativa, aesthetic procedure guidance, and the expanding landscape of HS therapeutics.
Dr Yoo and Dr Gottlieb reviewed the principles and applications of handheld ultrasound devices, sonographic assessment of hidradenitis suppurativa, aesthetic procedure guidance, and the expanding landscape of HS therapeutics.
Dr Yoo and Dr Gottlieb reviewed...
03/02/2026
The Dermatologist
Dr Heberton
Conference Coverage
Checkpoint Inhibitor Rashes: When to Treat, When to Rechallenge, and When It’s Not the Drug
02/22/2026
Riya Gandhi, MA
A clinical update on cutaneous immune-related adverse events from PD-1/PD-L1 inhibitors, covering lichenoid eruptions, psoriasis, bullous pemphigoid, dupilumab, steroid-sparing strategies, and immune checkpoint inhibitor rechallenge.
A clinical update on cutaneous immune-related adverse events from PD-1/PD-L1 inhibitors, covering lichenoid eruptions, psoriasis, bullous pemphigoid, dupilumab, steroid-sparing strategies, and immune checkpoint inhibitor rechallenge.
A clinical update on cutaneous...
02/22/2026
The Dermatologist
Dr Heberton
Conference Coverage
EGFR Inhibitor Rashes: Prophylaxis, Isotretinoin, and When to Culture
02/22/2026
Riya Gandhi, MA
A clinical update on cutaneous toxicities of epidermal growth factor receptor inhibitors, covering acneiform eruptions, paronychia, staphylococcal superinfection, xerosis, isotretinoin use, and amivantamab-specific toxicities.
A clinical update on cutaneous toxicities of epidermal growth factor receptor inhibitors, covering acneiform eruptions, paronychia, staphylococcal superinfection, xerosis, isotretinoin use, and amivantamab-specific toxicities.
A clinical update on cutaneous...
02/22/2026
The Dermatologist
Dr Blauvelt
Conference Coverage
Plaque Psoriasis Treatment Therapeutics: Oral IL-23 Inhibitors
02/22/2026
Riya Gandhi, MA
A clinical update on oral IL-23 therapy for plaque psoriasis, highlighting icotrokinra phase 3 data, superiority vs deucravacitinib, TYK2 inhibitors (zasocitinib, envudeucitinib), and patient-centered treatment strategies.
A clinical update on oral IL-23 therapy for plaque psoriasis, highlighting icotrokinra phase 3 data, superiority vs deucravacitinib, TYK2 inhibitors (zasocitinib, envudeucitinib), and patient-centered treatment strategies.
A clinical update on oral IL-23...
02/22/2026
The Dermatologist
Dr Wells
Conference Coverage
Oral Therapy in Psoriatic Arthritis: JAK, TYK2, and the End of Methotrexate Monotherapy?
02/22/2026
Riya Gandhi, MA
A clinical update on psoriatic arthritis diagnosis and oral therapy, highlighting JAK/STAT pathogenesis, apremilast (PALACE), deucravacitinib (POETYK PsA-1/2), methotrexate safety concerns, and individualized treatment strategies.
A clinical update on psoriatic arthritis diagnosis and oral therapy, highlighting JAK/STAT pathogenesis, apremilast (PALACE), deucravacitinib (POETYK PsA-1/2), methotrexate safety concerns, and individualized treatment strategies.
A clinical update on psoriatic...
02/22/2026
The Dermatologist
Dr Goff
Conference Coverage
Cutaneous T-Cell Lymphoma: When to Worry in MF/SS—and What’s Next in Targeted Therapy
02/22/2026
Riya Gandhi, MA
A dermatology update on mycosis fungoides and Sézary syndrome, covering NB-UVB remission data, spot radiation therapy, brentuximab, mogamulizumab, lacutamab (anti-KIR3DL2), and CD70-directed CAR-T therapy (volamcabtagene durzigedleucel).
A dermatology update on mycosis fungoides and Sézary syndrome, covering NB-UVB remission data, spot radiation therapy, brentuximab, mogamulizumab, lacutamab (anti-KIR3DL2), and CD70-directed CAR-T therapy (volamcabtagene durzigedleucel).
A dermatology update on mycosis...
02/22/2026
The Dermatologist
Dr Elman
Conference Coverage
Dermatomyositis: Interferon Biology, Steroid Dependence, and the Rise of JAK/TYK2 Targeting
02/21/2026
Riya Gandhi, MA
An update on dermatomyositis, highlighting interferon-driven pathogenesis, Cutaneous Dermatomyositis Disease Area and Severity Index outcomes, IVIG data, brepocitinib (dual JAK1/TYK2 inhibitor), steroid tapering strategies, and more.
An update on dermatomyositis, highlighting interferon-driven pathogenesis, Cutaneous Dermatomyositis Disease Area and Severity Index outcomes, IVIG data, brepocitinib (dual JAK1/TYK2 inhibitor), steroid tapering strategies, and more.
An update on dermatomyositis,...
02/21/2026
The Dermatologist
Dr Orgill
Conference Coverage
Reimagining HS Care in 2026: Earlier Diagnosis, Biologic Durability, and Smarter Surgery
02/21/2026
Riya Gandhi, MA
A dermatology update on hidradenitis suppurativa management, covering diagnostic delay, comorbidity screening, adalimumab (PIONEER), secukinumab (SUNSHINE/SUNRISE), bimekizumab (BE HEARD), infliximab, and more.
A dermatology update on hidradenitis suppurativa management, covering diagnostic delay, comorbidity screening, adalimumab (PIONEER), secukinumab (SUNSHINE/SUNRISE), bimekizumab (BE HEARD), infliximab, and more.
A dermatology update on...
02/21/2026
The Dermatologist
Dr Elman
Conference Coverage
Screening in the Biologic Era: Are Dermatologists Over- or Under-Monitoring in 2026?
02/21/2026
Riya Gandhi, MA
A clinical update on baseline and ongoing screening for biologics and JAK inhibitors in psoriasis and atopic dermatitis, covering tuberculosis testing, hepatitis B/C reactivation risk, lab monitoring, and vaccination strategies.
A clinical update on baseline and ongoing screening for biologics and JAK inhibitors in psoriasis and atopic dermatitis, covering tuberculosis testing, hepatitis B/C reactivation risk, lab monitoring, and vaccination strategies.
A clinical update on baseline...
02/21/2026
The Dermatologist
Dr Goff
Conference Coverage
Cosmetic Tools in Dermatologic Disease
02/21/2026
Riya Gandhi, MA
A dermatology update on cosmetic treatments for medical conditions, including hyaluronic acid fillers in scleroderma, fractional CO₂ laser with isotretinoin, tretinoin in rosacea, hyperdilute botulinum toxin for flushing, and more.
A dermatology update on cosmetic treatments for medical conditions, including hyaluronic acid fillers in scleroderma, fractional CO₂ laser with isotretinoin, tretinoin in rosacea, hyperdilute botulinum toxin for flushing, and more.
A dermatology update on cosmetic...
02/21/2026
The Dermatologist
Dr Alexis
Conference Coverage
Hyperpigmentation Therapeutics: From Hydroquinone Alternatives to Lasers and Oral Tranexamic Acid
02/21/2026
Riya Gandhi, MA
A clinical update on hyperpigmentation treatment, highlighting hydroquinone alternatives, thiamidol, cysteamine, oral tranexamic acid, polypodium leucotomos, 1927 nm fractional laser, and combination strategies.
A clinical update on hyperpigmentation treatment, highlighting hydroquinone alternatives, thiamidol, cysteamine, oral tranexamic acid, polypodium leucotomos, 1927 nm fractional laser, and combination strategies.
A clinical update on...
02/21/2026
The Dermatologist
Dr Alexis
Conference Coverage
Vitiligo: JAK Inhibitors, Combination Phototherapy, and Cell-Based Repigmentation
02/21/2026
Riya Gandhi, MA
A clinical update on nonsegmental vitiligo, highlighting ruxolitinib cream (TRuE-V), JAK inhibitors (povorcitinib, upadacitinib, ritlecitinib, baricitinib), oral minipulse dexamethasone, and autologous skin cell suspension transplantation.
A clinical update on nonsegmental vitiligo, highlighting ruxolitinib cream (TRuE-V), JAK inhibitors (povorcitinib, upadacitinib, ritlecitinib, baricitinib), oral minipulse dexamethasone, and autologous skin cell suspension transplantation.
A clinical update on...
02/21/2026
The Dermatologist
Dr Guttman
Conference Coverage
Atopic Dermatitis: OX40, IL-31, Treg Therapy, and the JAK Head-to-Head Era
02/21/2026
Riya Gandhi, MA
A dermatology update on atopic dermatitis therapeutics, highlighting dupilumab, lebrikizumab, nemolizumab, rocatinlimab (OX40), amlitelimab (OX40L), rezpegaldesleukin, and oral JAK inhibitors (upadacitinib, abrocitinib).
A dermatology update on atopic dermatitis therapeutics, highlighting dupilumab, lebrikizumab, nemolizumab, rocatinlimab (OX40), amlitelimab (OX40L), rezpegaldesleukin, and oral JAK inhibitors (upadacitinib, abrocitinib).
A dermatology update on atopic...
02/21/2026
The Dermatologist
Dr Yosipovitch
Conference Coverage
Chronic Itch in 2026: Targeting Th2, IL-31, BTK, and Beyond
02/21/2026
Riya Gandhi, MA
A clinical update on chronic pruritus management, highlighting dupilumab, lebrikizumab, nemolizumab, JAK inhibitors, remibrutinib (BTK inhibitor), povorcitinib, and opioid receptor modulators.
A clinical update on chronic pruritus management, highlighting dupilumab, lebrikizumab, nemolizumab, JAK inhibitors, remibrutinib (BTK inhibitor), povorcitinib, and opioid receptor modulators.
A clinical update on chronic...
02/21/2026
The Dermatologist
Dr Orgill
Conference Coverage
Mohs Reconstruction: When to Close, When to Refer, and the Evolving Role of Plastic Surgery
02/20/2026
Riya Gandhi, MA
A dermatology update on Mohs reconstruction, covering growth trends, peri-orbital and nasal defects, dermal regeneration templates, full-thickness grafts, bilobed and forehead flaps, and multidisciplinary care.
A dermatology update on Mohs reconstruction, covering growth trends, peri-orbital and nasal defects, dermal regeneration templates, full-thickness grafts, bilobed and forehead flaps, and multidisciplinary care.
A dermatology update on Mohs...
02/20/2026
The Dermatologist
Dr Guttman
Conference Coverage
Chronic Hand Eczema: From Pathogenic Subtypes to Targeted JAK and IL-4/13 Therapy
02/20/2026
Riya Gandhi, MA
A clinical update on chronic hand eczema, highlighting delgocitinib cream, ruxolitinib, gusacitinib, dupilumab, tralokinumab, and biomarker-driven Th1/Th2/Th17 endotypes.
A clinical update on chronic hand eczema, highlighting delgocitinib cream, ruxolitinib, gusacitinib, dupilumab, tralokinumab, and biomarker-driven Th1/Th2/Th17 endotypes.
A clinical update on chronic...
02/20/2026
The Dermatologist
Dr Merola
Conference Coverage
Cutaneous Lupus: Risk of Systemic Progression and a Rapidly Expanding Targeted Therapy Pipeline
02/20/2026
Riya Gandhi, MA
A clinical update on cutaneous lupus erythematosus and systemic lupus erythematosus (SLE), covering risk of progression from discoid lupus erythematosus to SLE, subacute cutaneous lupus drug triggers, and more.
A clinical update on cutaneous lupus erythematosus and systemic lupus erythematosus (SLE), covering risk of progression from discoid lupus erythematosus to SLE, subacute cutaneous lupus drug triggers, and more.
A clinical update on cutaneous...
02/20/2026
The Dermatologist
Conference Coverage
Allergy 101 for Dermatologists: What to Test, What to Treat, and What to Ignore
02/20/2026
Riya Gandhi, MA
An update for dermatology on allergy referrals, covering penicillin de-labeling, drug desensitization, food allergy testing, immunodeficiency evaluation, and when not to refer.
An update for dermatology on allergy referrals, covering penicillin de-labeling, drug desensitization, food allergy testing, immunodeficiency evaluation, and when not to refer.
An update for dermatology on...
02/20/2026
The Dermatologist
Dr Weber
Conference Coverage
From Psoriasis to Plaque: Why Cardiovascular Risk Belongs in Every Dermatology Visit
02/20/2026
Riya Gandhi, MA
A cardio-dermatology update on psoriasis, psoriatic arthritis, coronary computed tomography angiography, coronary artery calcium-AI imaging, and cardiovascular risk prevention in immune-mediated inflammatory disease.
A cardio-dermatology update on psoriasis, psoriatic arthritis, coronary computed tomography angiography, coronary artery calcium-AI imaging, and cardiovascular risk prevention in immune-mediated inflammatory disease.
A cardio-dermatology update on...
02/20/2026
The Dermatologist
Scott Elman, MD, FAAD
Conference Coverage
Systemic Sclerosis: From Vasculopathy to CAR-T—Where Are We Now?
02/20/2026
Riya Gandhi, MA
A clinical update on systemic sclerosis, covering pathogenesis, rituximab, nintedanib, tocilizumab, JAK inhibitors, CAR-T therapy, and evolving treatment strategies for skin and lung disease.
A clinical update on systemic sclerosis, covering pathogenesis, rituximab, nintedanib, tocilizumab, JAK inhibitors, CAR-T therapy, and evolving treatment strategies for skin and lung disease.
A clinical update on systemic...
02/20/2026
The Dermatologist
Dr Weber
Conference Coverage
GLP-1 Agonists in Psoriatic Disease: Beyond Weight Loss to Cardiovascular and Inflammatory Benefit
02/20/2026
Riya Gandhi, MA
A clinical update on GLP-1 receptor agonists in psoriasis and psoriatic arthritis, highlighting cardiovascular outcomes, SELECT trial data, obesity-driven inflammation, and combination therapy results.
A clinical update on GLP-1 receptor agonists in psoriasis and psoriatic arthritis, highlighting cardiovascular outcomes, SELECT trial data, obesity-driven inflammation, and combination therapy results.
A clinical update on GLP-1...
02/20/2026
The Dermatologist
Dr Kaufmann
Conference Coverage
PBMs, Vertical Integration, and State Reform: Why Dermatology Drug Costs Remain So High in 2026
02/20/2026
Riya Gandhi, MA
A dermatology update on pharmacy benefit managers, vertical integration, copay accumulators, rebate reform, and new state transparency laws affecting biologics and specialty drugs.
A dermatology update on pharmacy benefit managers, vertical integration, copay accumulators, rebate reform, and new state transparency laws affecting biologics and specialty drugs.
A dermatology update on pharmacy...
02/20/2026
The Dermatologist
Dr Economy
Conference Coverage
Pregnancy Dermatoses: The Itchy Patient, the Dangerous Diagnosis, and the Referral That Can’t Wait
02/20/2026
Riya Gandhi, MA
A clinical update on dermatoses in pregnancy, covering pruritus, atopic eruption of pregnancy, polymorphic eruption of pregnancy, pemphigoid gestationis, pustular psoriasis of pregnancy, and intrahepatic cholestasis of pregnancy.
A clinical update on dermatoses in pregnancy, covering pruritus, atopic eruption of pregnancy, polymorphic eruption of pregnancy, pemphigoid gestationis, pustular psoriasis of pregnancy, and intrahepatic cholestasis of pregnancy.
A clinical update on dermatoses...
02/20/2026
The Dermatologist
Dr Economy
Conference Coverage
Biologics, Immunosuppressives, and Pregnancy: What Dermatologists Need to Know in 2026
02/20/2026
Riya Gandhi, MA
A dermatology update on biologics and immunosuppressive therapy in pregnancy, covering TNF inhibitors, dupilumab, hydroxychloroquine, methotrexate contraindications, placental IgG transfer, and shared decision-making.
A dermatology update on biologics and immunosuppressive therapy in pregnancy, covering TNF inhibitors, dupilumab, hydroxychloroquine, methotrexate contraindications, placental IgG transfer, and shared decision-making.
A dermatology update on...
02/20/2026
The Dermatologist
Dr Cao
Conference Coverage
Ocular Red Flags in Dermatology: Uveitis, Cicatrizing Conjunctivitis, and Hydroxychloroquine Toxicity
02/20/2026
Riya Gandhi, MA
A 2026 Masterclasses update for dermatologists on uveitis classification, ocular cicatricial pemphigoid, Stevens-Johnson syndrome/toxic epidermal necrolysis complications, and revised hydroxychloroquine retinal toxicity screening guidelines.
A 2026 Masterclasses update for dermatologists on uveitis classification, ocular cicatricial pemphigoid, Stevens-Johnson syndrome/toxic epidermal necrolysis complications, and revised hydroxychloroquine retinal toxicity screening guidelines.
A 2026 Masterclasses update for...
02/20/2026
The Dermatologist
Dr Merola
Conference Coverage
Practical Serology Pearls for Dermatologists
02/20/2026
Riya Gandhi, MA
A 2026 Masterclasses update on autoimmune serologies in dermatology, covering antinuclear antibody testing, cutaneous lupus erythematosus, antiphospholipid antibodies, AVISE testing, drug-induced lupus, and hydroxychloroquine monitoring.
A 2026 Masterclasses update on autoimmune serologies in dermatology, covering antinuclear antibody testing, cutaneous lupus erythematosus, antiphospholipid antibodies, AVISE testing, drug-induced lupus, and hydroxychloroquine monitoring.
A 2026 Masterclasses update on...
02/20/2026
The Dermatologist
Dr Stidham
Conference Coverage
IBD for the Dermatologist: Extraintestinal Clues, Medication Overlap, and When to Refer
02/20/2026
Riya Gandhi, MA
A clinical update on inflammatory bowel disease for dermatologists, covering Crohn’s disease, ulcerative colitis, extraintestinal manifestations, erythema nodosum, pyoderma gangrenosum, hidradenitis suppurativa, and medication overlap.
A clinical update on inflammatory bowel disease for dermatologists, covering Crohn’s disease, ulcerative colitis, extraintestinal manifestations, erythema nodosum, pyoderma gangrenosum, hidradenitis suppurativa, and medication overlap.
A clinical update on...
02/20/2026
The Dermatologist
Conference Coverage
Systemic Mastocytosis in Dermatology: Diagnosis and Targeted Therapy
02/20/2026
Riya Gandhi, MA
A clinical update on systemic mastocytosis, KIT D816V mutations, avapritinib data from the PIONEER study, and multidisciplinary management.
A clinical update on systemic mastocytosis, KIT D816V mutations, avapritinib data from the PIONEER study, and multidisciplinary management.
A clinical update on systemic...
02/20/2026
The Dermatologist
Dr Mauskar
Conference Coverage
Vulvar Dermatology Decoded: Contact Dermatitis, Lichen Sclerosus, and the Menopause Overlap
02/20/2026
Riya Gandhi, MA
A 2026 Masterclasses update on vulvar dermatology, covering contact dermatitis, lichen sclerosus, lichen simplex chronicus, inverse psoriasis, hidradenitis suppurativa, and genitourinary syndrome of menopause.
A 2026 Masterclasses update on vulvar dermatology, covering contact dermatitis, lichen sclerosus, lichen simplex chronicus, inverse psoriasis, hidradenitis suppurativa, and genitourinary syndrome of menopause.
A 2026 Masterclasses update on...
02/20/2026
The Dermatologist
Dr Yoo
Conference Coverage
Why US Sunscreens Lag Behind and Why It Matters for Melasma and Skin of Color
02/19/2026
Riya Gandhi, MA
A sunscreen update, covering UVA1, visible light, iron oxides, tinted sunscreen, and global filter differences impacting hyperpigmentation and melasma.
A sunscreen update, covering UVA1, visible light, iron oxides, tinted sunscreen, and global filter differences impacting hyperpigmentation and melasma.
A sunscreen update, covering...
02/19/2026
The Dermatologist
Dr Cao
Conference Coverage
Ophthalmology Essentials for Dermatologists: Dry Eye, Cataracts, and Glaucoma in Clinical Practice
02/19/2026
Riya Gandhi, MA
A practical ophthalmology update for dermatologists. covering dry eye syndrome, cataract surgery thresholds, glaucoma risk factors, and when to refer.
A practical ophthalmology update for dermatologists. covering dry eye syndrome, cataract surgery thresholds, glaucoma risk factors, and when to refer.
A practical ophthalmology update...
02/19/2026
The Dermatologist
Dr Glick
Conference Coverage
Rethinking Seborrheic Dermatitis in 2026: PDE4 Inhibitors, Luliconazole, and Microbiome-Driven Care
02/19/2026
Riya Gandhi, MA
A clinical update on seborrheic dermatitis, featuring roflumilast foam, luliconazole shampoo, JAK inhibitors, biologics, and microbiome-targeted therapies.
A clinical update on seborrheic dermatitis, featuring roflumilast foam, luliconazole shampoo, JAK inhibitors, biologics, and microbiome-targeted therapies.
A clinical update on seborrheic...
02/19/2026
The Dermatologist
Dr Stidham
Conference Coverage
Artificial Intelligence in Dermatology: From Proof of Concept to Real-World Accountability
02/19/2026
Riya Gandhi, MA
How are artificial intelligence, large language models, and multimodal systems reshaping dermatology?
How are artificial intelligence, large language models, and multimodal systems reshaping dermatology?
How are artificial intelligence,...
02/19/2026
The Dermatologist
Dr Siegel
Conference Coverage
AI, Smart Screening, and Smart Glasses: What Dermatologists Need to Know About Tech in 2026
02/19/2026
Riya Gandhi, MA
A dermatology technology update, covering artificial intelligence documentation risks, Doximity tools, SkinVision, DermaSensor, DermTech Smart Sticker, smart glasses, and medicolegal considerations.
A dermatology technology update, covering artificial intelligence documentation risks, Doximity tools, SkinVision, DermaSensor, DermTech Smart Sticker, smart glasses, and medicolegal considerations.
A dermatology technology update,...
02/19/2026
The Dermatologist
Dr Yoo
Conference Coverage
Dermatologic Ultrasound in 2026: Cosmetics and Hidradenitis Suppurativa
02/19/2026
Riya Gandhi, MA
A clinical update on dermatologic ultrasound, covering cosmetic filler mapping, vascular complication management, hidradenitis suppurativa (HS) tunnel detection, and emerging HS biologics.
A clinical update on dermatologic ultrasound, covering cosmetic filler mapping, vascular complication management, hidradenitis suppurativa (HS) tunnel detection, and emerging HS biologics.
A clinical update on...
02/19/2026
The Dermatologist
Blauvelt
Videos
Oral IL-23 Therapies in Psoriasis: Addressing Undertreatment, Adherence, and Patient Preference
02/17/2026
Riya Gandhi, MA
Dr Andrew Blauvelt discusses how emerging oral IL-23 therapies may address persistent gaps in psoriasis care, including undertreatment and nonadherence.
Dr Andrew Blauvelt discusses how emerging oral IL-23 therapies may address persistent gaps in psoriasis care, including undertreatment and nonadherence.
Dr Andrew Blauvelt discusses how...
02/17/2026
The Dermatologist

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use